POPULATION PHARMACOKINETIC MODELS - MEASURES OF CENTRAL TENDENCY

被引:16
作者
DODGE, WF
JELLIFFE, RW
RICHARDSON, CJ
BELLANGER, RA
HOKANSON, JA
SNODGRASS, WR
机构
[1] Division of Clinical Pharmacology, Department of Pediatrics, University of Texas Medical Branch, Galveston, Texas
[2] Laboratory of Applied Pharmacokinetics, Department of Medicine, University of Southern California School of Medicine, Los Angeles, California
[3] Division of Neonatology, Department of Pediatrics, University of Texas Medical Branch, Galveston, Texas
[4] Department of Preventive Medicine and Community Health, University of Texas Medical Branch, Galveston, Texas
[5] Pediatric Clinical Pharmacology, University of Texas Medical Branch, Galveston, Texas
来源
DRUG INVESTIGATION | 1993年 / 5卷 / 04期
关键词
D O I
10.1007/BF03258448
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The availability of personal computer programs for individualising drug dosage regimens has stimulated interest in modelling population pharmacokinetics. Appropriate use of population models requires knowledge of the distribution of their pharmacokinetic parameter values. If non-Gaussian, it is imperative not to assume that the arithmetic mean is the best measure of central tendency. This has important consequences for therapeutic drug monitoring and for individualising drug dosage regimens. Utilising a new nonparametric expectation maximisation (NPEM) population modelling program and retrospective data from 129 preterm infants who received gentamicin in our own clinical setting, we developed 2 population models. The NPEM algorithm showed that both had significant non-Gaussian distributions of their parameter values (e.g. the mean value for the volume of distribution exceeded the 75th percentile). Although the median parameter values demonstrated only slightly better predictive accuracy than the mean, its choice as the measure of central tendency was associated with excellent agreement between the goal and the subsequently observed average initial peak serum gentamicin concentrations (i.e. 6.0 vs 6.2 mg/L). In contrast, simulation using the mean parameter values predicted an average concentration 30% greater than the goal (i.e. 8.0 vs 6.0 mg/L). Thus, for this group of patients, the median proved a better measure of central tendency.
引用
收藏
页码:206 / 211
页数:6
相关论文
共 16 条
[1]  
Beal S., Asymptotic properties of optimization estimates for the independent net identically distributed case with application to extended least-squares estimates, (1984)
[2]  
Beal S., Population pharmacokinetic data and parameter estimation based on their first two statistical moments, Drug Metabolism Reviews, 16, pp. 173-193, (1984)
[3]  
Beal S., Sheiner L., NONMEM users guide — part 1: Users basic guide, (1980)
[4]  
Dodge W.F., Jelliffe R.W., Richardson C.J., Bellanger R.A., Hokanson J.A., Et al., Gentamicin population pharmacokinetic models for low birthweight infants using a new nonparametric method, Clinical Pharmacology and Therapeutics, 50, pp. 25-31, (1991)
[5]  
Dubowitz L.M.S., Dubowitz V., Goldberg C., Clinical assessment of gestational age in the newborn infant, Journal of Pediatrics, 77, pp. 1-10, (1970)
[6]  
Gibbons J.D., Nonparametric methods for quantitative analysis, (1976)
[7]  
Hurst A., Yoshinaga M., Mitani G., Foo K., Jelliffe R., Et al., Application of Bayesian method to monitor and adjust vancomycin dosage regimens, Antimicrobial Agents and Chemotherapy, 34, pp. 165-1171, (1990)
[8]  
Jelliffe R.W., Clinical applications of pharmacokinetics and control theory: planning, monitoring, and adjusting dosage regimens of aminoglycosides, lidocaine, digitoxin and digoxin, Topics in clinical pharmacology and therapeutics, pp. 26-82, (1986)
[9]  
Jelliffe R.W., Explicit determination of laboratory assay error patterns — a useful aid in therapeutic drug monitoring. ASCP Clinical Pharmacology Check Sample No. DM 89-4 (DM-56), American Society of Clinical Pathologists, (1989)
[10]  
Mallet A., A maximum likelihood estimation method for random coefficient regression models, Biometrika, 73, pp. 654-656, (1986)